<DOC>
	<DOCNO>NCT01946412</DOCNO>
	<brief_summary>The purpose study provide information regard long-term safety pharmacodynamics ivacaftor treatment pediatric population young 6 year age Cystic Fibrosis ( CF ) CFTR gate mutation least 1 allele explore efficacy long-term ivacaftor treatment population patient CF .</brief_summary>
	<brief_title>Roll-Over Study Ivacaftor Cystic Fibrosis Pediatric Subjects With CF Transmembrane Conductance Regulator Gene ( CFTR ) Gating Mutation</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Inclusion Criteria ( Ivacaftor Arm ) : 1 . Completed last study visit treatment period previous study ( NCT01705145 ) 2 . Hematology , serum chemistry , vital sign result Day 1 clinically significant abnormality would interfere study assessment , judge investigator 3 . As judged investigator , parent legal guardian must able understand protocol requirement , restriction , instruction parent legal guardian able ensure subject assent participation study degree subject assent , subject comply likely complete study plan Inclusion Criteria ( Observational Arm ) : 1 . Subjects complete assigned study drug treatment previous study ( NCT01705145 ) elect enroll ivacaftor arm subject prematurely discontinue treatment previous study receive least 1 dose study drug treatment previous study eligible enrollment observational arm . Exclusion Criteria ( Ivacaftor Arm ) : 1 . Subjects prematurely discontinue previous study 2 . History illness condition , opinion investigator , might confound result study pose additional risk administer study drug subject 3 . Subjects history study treatment intolerance observe previous study , opinion investigator , might pose additional risk administer study drug subject 4 . Subjects receive commerciallyavailable ivacaftor treatment 5 . Subject unable complete adequate slitlamp examination last ophthalmologic examination previous study ( Observational Arm ) 1 . Subjects receive ivacaftor treatment eligible enrollment observational arm .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Cystic Fibrosis</keyword>
</DOC>